Chronic hepatitis B virus (HBV) infection is a common cause of advanced liver disease and hepatocellular carcinoma and has become a worldwide public health issue. Liver transplantation (LT) is the most effective therapeutic option for HBV-infected patients who have acute or chronic liver failure and
Hepatitis B virus–specific CD4 T cell immunity after liver transplantation for chronic hepatitis B
✍ Scribed by Ying Luo; Chung Mau Lo; Cindy K. Cheung; George K. Lau; John Wong
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 140 KB
- Volume
- 15
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21674
No coin nor oath required. For personal study only.
✦ Synopsis
Cellular immunity plays an important role in the long-term control of hepatitis B virus (HBV) infection. We studied the changes in HBV-specific CD4 T cell immunity after orthotopic liver transplantation (OLT) for chronic hepatitis B under antiviral prophylaxis. T cell proliferation and interferon-␥ production in response to in vitro challenge with HBV-encoded antigens were tested in 40 OLT recipients without HBV recurrence and in 12 OLT recipients with HBV recurrence more than 1 year after transplantation, and they were compared to 40 subjects with chronic HBV infection and to 23 subjects with self-limited HBV infection. The frequency and magnitude of the HBV-specific CD4 T cell response were significantly lower in 40 OLT recipients with HBV clearance, but the T cell reactivity to mitogen (phytohemagglutinin) and recall antigen (tetanus toxoid) was maintained. In the 12 OLT recipients with HBV recurrence, however, the HBV-specific T cell immunity was enhanced to a level comparable to that of patients with chronic hepatitis B, and the level was dependent on the serum viral load. In conclusion, HBV-specific CD4 T cell immunity is antigen-driven and evanesces with viral clearance, hence providing a favorable milieu for reactivation once prophylaxis is withdrawn. The cellular immunity in recipients with recurrence is not significantly different from that of individuals with chronic hepatitis B.
📜 SIMILAR VOLUMES
Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is associated with poor graft-and patientsurvival. Treatment with HBV-specific immunoglobulins (HBIG) in combination with nucleos(t)ide analogs is effective in preventing HBV reinfection of the graft and improving OLT ou
et al., 1 published in the January issue of Liver Transplantation, describing 2 cases of spontaneously cleared hepatitis C virus (HCV) infection in human immunodeficiency virus-coinfected patients early after liver transplantation. The cause for HCV clearance in those cases remained unclear. We rece
"Escape" variants of hepatitis B virus (HBV) can cause infection despite previous immunization. These viruses show alterations of the immunogenic major hydrophilic loop of the HBV small surface protein (s-protein). We studied whether HBV "escape" variants were selected in patients with graft infecti
Immunoprophylaxis using intravenous (IV) hepatitis B immune globulin (HBIG) decreases the recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). However, IV HBIG is expensive, has significant side effects, and is inconvenient to administer. An alternative appro